

22 April 2026

ASX Announcement

## Firebrick investor webinar update

---

**Firebrick Pharma Limited (ASX:FRE) (Firebrick, Company)** is pleased to announce that it will hold an investor webinar to update shareholders, investors and other interested parties. This follows recent news from the Company including the approval of Nasodine Nasal Spray in Indonesia and the \$1.5m Placement.

Executive Chair Dr Peter Molloy will present the webinar at **11am AEST on Monday 27 April 2026**.

To register to attend the webinar please visit:

[https://us02web.zoom.us/webinar/register/WN\\_mBYQG\\_zXSuWuRC-XNFelwA](https://us02web.zoom.us/webinar/register/WN_mBYQG_zXSuWuRC-XNFelwA)

A recording will be available at the above link shortly after the conclusion of the live session, and the replay will also be available via the Company's website and social media channels.

Questions can be submitted on the day or sent in advance to:

[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman of Firebrick Pharma Limited.

- ENDS -

### About Firebrick (ASX:FRE)

Firebrick Pharma is developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). Its first product, Nasodine® Nasal Spray (0.5% PVP-I), has been introduced into the United States, Singapore, and Fiji & South Pacific. The Company is pursuing approval in other markets, including the Philippines. Nasodine® Throat Spray is the first follow-on product, now available in Singapore and Fiji. For further information, visit <https://nasodine-sg.com/>

### Contacts:

**Media contact:**

Matthew Wright, NWR Communications  
[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

**Shareholder Company contact:**

Kam Watson, Firebrick Pharma  
[investors@firebrickpharma.com](mailto:investors@firebrickpharma.com)